Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …Sacramento BeeMeanwhile, Biogen and partner Abbott (NYSE:ABT) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is bein…
Organ donor event raises more than $5000 – Alton Telegraph
Organ donor event raises more than $5000Alton TelegraphBy DAN BRANNAN The Spring Organ/Donor/Tissue Donation Awareness 5K Run/2-Mile Walk once again created awareness and funds for donor registration and the Jersey Community Hospital Emergency Room exp…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's … – PR Newswire (press release)
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …PR Newswire (press release)Meanwhile, Biogen and partner Abbott (NYSE: ABT) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Dacl…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's … – NASDAQ
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …NASDAQMeanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated…
BioVentrix Selected to Present at Prestigious EuroPCR Meeting – Reuters
BioVentrix Selected to Present at Prestigious EuroPCR MeetingReutersPARIS–(Marketwire – May 14, 2012) – BioVentrix, the developer of minimally invasive therapies for the treatment of heart failure, was selected to present at EuroPCR, the annual meetin…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's … – InvestorIdeas.com (press release)
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …InvestorIdeas.com (press release)Meanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) i…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's … – Zacks.com
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …Zacks.comMeanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab …
BG Medicine Announces Publication of First Study on Use of Galectin-3 in … – MarketWatch (press release)
BG Medicine Announces Publication of First Study on Use of Galectin-3 in …MarketWatch (press release)The galectin-3 CORONA study was designed to assess whether baseline galectin-3 levels could distinguish a group of patients with heart failure who wo…
Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
LAWRENCE, Mass., May 14, 2012 /PRNewswire/ — NxStage® Medical, Inc. (NXTM), a leading manufacturer of innovative dialysis products, today announced that former NxStage® System One™ patient Nikolas …
Lack of timely transport is an issue for getting organ transplantation – Royal Gazette
Lack of timely transport is an issue for getting organ transplantationRoyal GazetteBy Sam Strangeways Dr Stefan G Tullius, MD, PhD, FACS Chief, Division of Transplant Surgery Director, Transplant Surgery Research Laboratory Brigham & Women?s Hospit…